Newswise — The bacteria that reside on and within our bodies are known to have a significant influence on our health. New research suggests wiping out the gut microbiota could improve heart functioning and potentially slow the cardiac damage that occurs with heart failure.

The research is based on the idea that microbes living in the gastrointestinal tract affect heart failure by increasing the production of T cells, a type of immune cell. Researchers found mice with induced heart failure fared better if they were treated with antibiotics for five weeks, essentially sterilizing the gut.

“Our lab studies how the gut talks to the heart through T cells,” said Francisco J. Carrillo-Salinas, PhD, a postdoctoral scholar at Tufts University who conducted the research. “Given that the gut is the body’s largest reservoir of T cells and microbes, by modulating the microbiota we could modulate T cell activation and changes in the heart that lead to heart failure.”

Carrillo-Salinas will present the research at the American Society for Investigative Pathology annual meeting during the 2018 Experimental Biology meeting, held April 21-25 in San Diego.

Heart failure is a condition in which the heart cannot pump enough blood to meet the body’s needs. Nearly 6 million Americans have heart failure, and about half of people diagnosed with heart failure die within five years.

Carrillo-Salinas’ group has previously shown that T cells infiltrate the heart in patients with heart failure. Inflammation, which is a consequence of the immune response, also is known to play important roles in heart disease.

Other research has suggested disruption of the gut microbiota can affect cardiovascular health. The gut microbiota can be altered by dietary changes or the use of antibiotics.

To decipher how changes in the gut microbiota affect T cell activity in the heart, the researchers examined markers of cardiovascular functioning and proteins relevant to immune activity in four groups of mice. Half of the mice received a cocktail of broad-spectrum antibiotics for five weeks that completely depleted bacteria from the gut. Half of those receiving the antibiotics and half of those not receiving the antibiotics also underwent a procedure to modify the aorta in a way that mimics the effects of heart failure in humans.

Among mice with induced heart failure, those that received antibiotics showed significantly better heart pumping ability and less damage to the heart tissue compared to those that did not receive antibiotics.

“Because complete sterilization of the gut has proven to ameliorate some experimental models of T cell mediated diseases, our results were in agreement with our initial hypothesis,” said Carrillo-Salinas. “The fact that we see fully preserved heart function is surprising, and I am looking forward to exciting new data on what happens in the heart once different bacteria recolonize the gut.”

The results suggest that T cells are activated in the lymph nodes located nearest the heart, move into the heart and then contribute to heart failure progression by releasing signaling proteins known as cytokines and inducing the heart to become enlarged and form scar tissue. All of these changes were prevented in the mice that received antibiotics.

“Understanding how the gut microbiota directly regulates the function of distant organs such as the heart will shed new light into potential new therapeutic approaches in patients recently diagnosed with heart failure to prevent progression,” said Carrillo-Salinas. “Our results demonstrate that gut microbiota depletion prevents cardiac dysfunction and set the stage for future studies that will determine which components of the microbiota are responsible for heart failure progression.”

Francisco Carrillo-Salinas will present this research on Monday, April 23, from 2:30–2:45 p.m. in Room 5A, San Diego Convention Center (abstract). Contact the media team for more information or to obtain a free press pass to attend the meeting.

Image available.

About Experimental Biology 2018

Experimental Biology is an annual meeting that attracts more than 14,000 scientists and exhibitors from five host societies and more than two dozen guest societies. With a mission to share the newest scientific concepts and research findings shaping clinical advances, the meeting offers an unparalleled opportunity for exchange among scientists from across the U.S. and the world who represent dozens of scientific areas, from laboratory to translational to clinical research. www.experimentalbiology.org #expbio

About the American Society for Investigative Pathology (ASIP)

ASIP is a society of biomedical scientists who investigate mechanisms of disease. Investigative pathology is an integrative discipline that links the presentation of disease in the whole organism to its fundamental cellular and molecular mechanisms. ASIP advocates for the practice of investigative pathology and fosters the professional career development and education of its members. www.asip.org

Find more news briefs and tipsheets at: https://www.eurekalert.org/meetings/eb/2018/newsroom.

Meeting Link: The Experimental Biology 2018 meeting, April 21–25,2018